Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture

Bone

Volumn 68, Issue , 2014, Pages 124-130

  Driessen, Johanna H M ^a,b,c   van Onzenoort, Hein A W ^c,d   Henry, Ronald M A ^c,e   Lalmohamed, Arief ^a,f   van den Bergh, Joop P ^c,g,h   Neef, Cees ^b,c   Leufkens, Hubert G M ^a   de Vries, Frank ^a,b,c,i  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g VIECURI MEDICAL CENTER   (Netherlands)

^h HASSELT UNIVERSITY   (Belgium)

ⁱ SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cohort study; CPRD; Diabetes mellitus type 2; DPP; Fracture

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DRUG USE; FEMALE; FRACTURE; GENDER; HAZARD RATIO; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; VERY ELDERLY; ADOLESCENT; CASE CONTROL STUDY; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84908602511     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.07.030     Document Type: Article

References (27)

1. Odén A., McCloskey E.V., Johansson H., Kanis J.A. Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 2013, 92(1):42-49.
2. Cooper C., Campion G., Melton L.J. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992, 2:285-289.
3. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007, 18(4):427-444.
4. Bazelier M.T., Gallagher A.M., van Staa T.P., Cooper C., Leufkens H.G., Vestergaard P., et al. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?. Pharmacoepidemiol Drug Saf 2012, 21(5):507-514.
5. Bazelier M.T., Vestergaard P., Gallagher A.M., van Staa T.P., Cooper C., Leufkens H.G., et al. Risk of fracture with thiazolidinediones: disease or drugs?. Calcif Tissue Int 2012, 26(9):2271-2279.
6. Betteridge D.J. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med 2011, 28(7):759-771.
7. Schwartz A.V., Vittinghoff E., Bauer D.C., Hillier T.A., Strotmeyer E.S., Ensrud K.E., et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011, 305(21):2184-2192.
8. Cooper C., Melton L.J. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992, 3(6):224-229.
9. Nuche-Berenguer B., Moreno P., Esbrit P., Dapía S., Caeiro J.R., Cancelas J., et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 2009, 84:453-461.
10. Nuche-Berenguer B., Moreno P., Portal-Nuñez S., Dapía S., Esbrit P., Villanueva-Peñacarrillo M.L. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 2010, 159(1-3):61-66.
11. Moreno P., Nuche-Berenguer B., Gutiérrez-Rojas I., Acitores A., Sancho V., Valverde I., et al. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states. J Mol Endocrinol 2012, 48:37-47.
12. Nuche-Berenguer B., Portal-Núñez S., Moreno P., González N., Acitores A., López-Herradón A., et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 2010, 225(2):585-592.
13. Kim J.Y., Lee S.K., Jo K.J., Song D.Y., Lim D.M., Park K.Y., et al. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci 2013, 92:533-540.
14. Monami M., Dicembrini I., Antenore A., Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011, 34(11):2474-2476.
15. Bunck M.C., Poelma M., Eekhoff E.M., Schweizer A., Heine R.J., Nijpels G., et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 2012, 4(2):181-185.
16. Van Staa T.P., Abenhaim L., Cooper C., Zhang B., Leufkens H.G. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000, 9(5):359-366.
17. Anonymous ATC classification index with DDDs 2002 2002, WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, Nydalen.
18. FRAX WHO Fracture Risk Assessment Tool [shef.ac.uk]. http://www.shef.ac.uk/FRAX/index.aspx.
19. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369(14):1317-1326.
20. Bunck M.C., Eliasson B., Corner A., Heine R.J., Shaginian R.M., Taskinen M.R., et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13:374-377.
21. Lamari Y., Boissard C., Moukhtar M.S., Jullienne A., Rosselin G., Garel J.M. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett 1996, 393(2-3):248-252.
22. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998, 280:2077-2082.
23. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
24. Kemmler W., Häberle L., von Stengel S. Effects of exercise on fracture reduction in older adults: a systematic review and meta-analysis. Osteoporos Int 2013, 24(7):937-950.
25. Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013, 9:155-163.
26. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19(4):385-397.
27. Rathmann W., Kostev K., Gruenberger J.B., Dworak M., Bader G., Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013, 15(1):55-61.